Amgen Inc (AMGN) 125.75 $AMGN
Final Glance: Biotechnology companies
AP - Thu Aug 07, 5:13PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.05% Sell Off
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.05%
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Midday Glance: Biotechnology companies
AP - Thu Aug 07, 12:31PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:40AM CDT
NPS Pharma (NPSP) reported earnings of 2 cents in the second quarter , which compared favorably with the Zacks Consensus Estimate.
Ligand Gains on Q2 Earnings Beat, Increases Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 10:32AM CDT
Ligand Pharmaceuticals reported better-than-expected second quarter 2014 results and raised its guidance.
Early Glance: Biotechnology companies
AP - Thu Aug 07, 9:58AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the Day
PR Newswire - Thu Aug 07, 8:30AM CDT
Zacks Equity Research highlights Take Two Interactive (Nasdaq:TTWO-Free Report) as the Bull of the Day and Loews Corp (NYSE:L-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAmgen (Nasdaq:AMGN-Free Report), Vertex (Nasdaq:VRTX-Free Report) and Regeneron (Nasdaq:REGN-Free Report).
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Celebrating 20 Years of The Motley Fool Online
David Gardner and Tom Gardner, The Motley Fool - Motley Fool - Mon Aug 04, 3:01PM CDT
This was written by brothers and Fool co-founders David and Tom Gardner. Twenty years ago today, on Aug. 4, 1994, The Motley Fool was born online. We'd started a year before as a print newsletter for friends and family. It was truly motley:...
Why Amgen (AMGN) Stock Is Up Today
at The Street - Mon Aug 04, 2:15PM CDT
Amgen,(AMGN) stock is up after the company said a late-stage study found that its blood cancer drug helped patients live significantly longer without the disease worsening, compared with standard treatment.
Nasdaq Leads In Quiet Session; Priceline Nears Buy Point
at Investor's Business Daily - Mon Aug 04, 1:53PM CDT
Stocks traded quietly higher in light volume with a little more than one hour remaining in Monday's session. The Nasdaq and S&P led the way, rising 0.5% and 0.4% respectively. The Dow Jones industrial average added 0.2%. Volume on the NYSE and Nasdaq...
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Amgen (AMGN) Crosses Pivot Point Resistance at $126.98
Comtex SmarTrend(R) - Mon Aug 04, 9:02AM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $125.87 today and have reached the first resistance level of $126.98. Should the shares continue to rise, the resistance pivots of $128.41 and $130.95 will be of interest.
S&P Down 3% - What's on Sale? - Ahead of Wall Street
Mark Vickery - Zacks Investment Research - Mon Aug 04, 8:36AM CDT
Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting stronger quarterly data.
Final Glance: Biotechnology companies
AP - Thu Aug 07, 5:13PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.05% Sell Off
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.05%
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Midday Glance: Biotechnology companies
AP - Thu Aug 07, 12:31PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:40AM CDT
NPS Pharma (NPSP) reported earnings of 2 cents in the second quarter , which compared favorably with the Zacks Consensus Estimate.
Ligand Gains on Q2 Earnings Beat, Increases Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 10:32AM CDT
Ligand Pharmaceuticals reported better-than-expected second quarter 2014 results and raised its guidance.
Early Glance: Biotechnology companies
AP - Thu Aug 07, 9:58AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the Day
PR Newswire - Thu Aug 07, 8:30AM CDT
Zacks Equity Research highlights Take Two Interactive (Nasdaq:TTWO-Free Report) as the Bull of the Day and Loews Corp (NYSE:L-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAmgen (Nasdaq:AMGN-Free Report), Vertex (Nasdaq:VRTX-Free Report) and Regeneron (Nasdaq:REGN-Free Report).
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Celebrating 20 Years of The Motley Fool Online
David Gardner and Tom Gardner, The Motley Fool - Motley Fool - Mon Aug 04, 3:01PM CDT
This was written by brothers and Fool co-founders David and Tom Gardner. Twenty years ago today, on Aug. 4, 1994, The Motley Fool was born online. We'd started a year before as a print newsletter for friends and family. It was truly motley:...
Why Amgen (AMGN) Stock Is Up Today
at The Street - Mon Aug 04, 2:15PM CDT
Amgen,(AMGN) stock is up after the company said a late-stage study found that its blood cancer drug helped patients live significantly longer without the disease worsening, compared with standard treatment.
Nasdaq Leads In Quiet Session; Priceline Nears Buy Point
at Investor's Business Daily - Mon Aug 04, 1:53PM CDT
Stocks traded quietly higher in light volume with a little more than one hour remaining in Monday's session. The Nasdaq and S&P led the way, rising 0.5% and 0.4% respectively. The Dow Jones industrial average added 0.2%. Volume on the NYSE and Nasdaq...
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Amgen (AMGN) Crosses Pivot Point Resistance at $126.98
Comtex SmarTrend(R) - Mon Aug 04, 9:02AM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $125.87 today and have reached the first resistance level of $126.98. Should the shares continue to rise, the resistance pivots of $128.41 and $130.95 will be of interest.
S&P Down 3% - What's on Sale? - Ahead of Wall Street
Mark Vickery - Zacks Investment Research - Mon Aug 04, 8:36AM CDT
Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting stronger quarterly data.
